The Total Synthesis of Phainanoids A-F
The Total Synthesis of Phainanoids A-F
批准号:
9756161
负责人:
Cody Ross Pitts
金额:
$6.16万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-01 至 2022-08-31
关键词:
AchievementAddressAlcoholsAttentionAutoimmune DiseasesB-LymphocytesBiologicalCatalysisChemicalsChemistryCollaborationsComplexCyclizationCyclobutanesCyclosporineDevelopmentDigit structureEvaluationHydrogenHydrogenationImmunologistImmunologyImmunosuppressive AgentsInvestigationLaboratoriesLactonesMedicineMethodologyMethodsModernizationModificationNatural ProductsObstructionParentsPharmaceutical ChemistryPharmaceutical PreparationsPharmacologic SubstancePlayProtocols documentationProtonsResearchRoleSavingsSirolimusSkeletonSpironolactoneStructureStructure-Activity RelationshipT-Cell ProliferationT-LymphocyteTestingTimeTransplantationVariantWorkbasecarbon skeletoncombatdesigndrug candidateenolateexperiencehuman diseaseimprovedin vitro activityinsightmethod developmentnanomolarnoveloxidationpreventrapid techniquescaffoldside effect
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Natural products and natural product derivatives continue to play a prominent role in the discovery and
development of pharmaceuticals to treat human diseases. In nearly all instances, the critical barrier to the
evaluation, modification, and application of natural products as drugs is accessibility. Specific to this proposal,
consider the recently discovered "phainanoid" natural products. This new class of structurally-complex
triterpenoids has demonstrated extremely potent immunosuppressive activity with IC50 values in single-digit
nanomolar concentrations (prior to any medicinal chemistry-inspired modification/improvement). The so-called
phainanoid F, in particular, is 7 and 221 times more active against the proliferation of T and B cells, respectively,
than cyclosporine A – a commercial immunosuppressant notably on the WHO's List of Essential Medicines.
Thus, it is evident that the phainanoids could represent promising and insightful lines of inquiry for the
development of a new class of immunosuppressive drugs; however, further investigation is currently hindered
by the aforementioned problem of accessibility. One viable solution to this problem is a concise, efficient total
synthesis strategy that is ideally amenable to various late-stage modifications for medicinal chemistry.
Accordingly, the specific aims of this proposal are 1) to develop a strategy for a practical total synthesis of
phainanoids A-F and 2) to create avenues for late-stage modifications of the phainanoids in order to study
structure-activity relationships. The total synthesis strategy proposed herein seeks to obtain the phainanoids in
as little as 18- to 21-step longest linear sequences, and it employs several modern synthetic methods in order
to maximize efficiency, scalability, and step savings. Among these are cutting-edge decarboxylative olefination
tactics, electrochemical oxidations, photochemical rearrangements, catalysis, and directed C-H functionalization
chemistry, as well as a proposed opportunity for method development (i.e. an intramolecular decarboxylative
olefination variant). Furthermore, the synthesis is designed such that the unique spirocyclic motifs on the
phainanoid carbon skeleton strategically are installed very late in the sequence, as these are believed, in large
part, to be most responsible for the observed biological activity. Considering there is preliminary evidence for
dramatic influence of the spirolactone segment on immunosuppressive activity, special attention is paid to its
independent synthesis/installation. Thus, a successful execution of this synthesis will open up a door for rapid
and easy diversification of the phainanoids (e.g. employing contemporary fluorofunctionalization tactics), and
subsequently all derivatives will be tested for activity in collaboration with an immunology laboratory. In all, this
will allow efficient analysis of structure-activity relationships and, hopefully, provide insight as to how to improve
the phainanoids as potential immunosuppressive drug candidates.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Synthetic Methods to Make Emerging Fluorinated Groups More Accessible
-
批准号:10713419
-
项目类别:
-
资助金额:$33.15万
-
财政年份:2023
-
负责人:Cody Ross Pitts
-
依托单位:
海外基金